The direct-acting antiviral glecaprevir/pibrentasvir (Mavyret) was highly effective and well tolerated in adults with acute ...

Mental health conditions are common among veterans and may play a larger role than previously recognized in raising liver ...

HCV—can persist in the livers of those infected and even lead to liver disease or failure in extreme cases. It affects tens ...

Giving postpartum mothers with hepatitis C the opportunity to start antiviral treatment while still in the hospital after giving birth — and delivering the medication to their bedside before discharge ...

BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral ...

Chronic hepatitis C infection has been linked to a higher risk of pancreatic cancer. Learn more about findings from a major ...

Detailed price information for Atea Pharmaceuticals Inc (AVIR-Q) from The Globe and Mail including charting and trades.

Public Health Reports (1974-), Vol. 131, No. 3 (MAY/JUNE 2016), pp. 430-437 (8 pages) Objective. New, highly effective hepatitis C virus (HCV) medications recently changed the landscape of HCV ...

WASHINGTON/NEW YORK (Reuters) - Merck & Co won U.S. approval on Friday to sell a new drug considered a major advance against the liver-destroying hepatitis C virus. Victrelis is expected to help ...

In 1989, Prof. Charles M. Rice, virology, undertook the project of developing a treatment for hepatitis C based on the vaccine that was successful in combating yellow fever. Despite similarities in ...

As hepatitis B research progresses, achieving higher functional cure rates is becoming more feasible. It is vital that ...